Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny study tests ablation for tough heart condition – but ends early

NCT ID NCT04282850

First seen Jan 26, 2026 · Last updated Jun 22, 2026 · Updated 22 times

Summary

This pilot study compared a heart ablation procedure (pulmonary vein isolation) to standard medications for managing atrial fibrillation in people with heart failure with preserved ejection fraction. Only 13 participants were enrolled before the study was terminated early. The main goal was to see if ablation could reduce the amount of time spent in atrial fibrillation and improve exercise capacity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Inova Heart and Vascular Institute

    Fairfax, Virginia, 22031, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pulmonary vein isolation (a heart ablation procedure)

What this could lead to

If successful, this could show that ablation improves exercise capacity and reduces AF burden better than medications alone for people with both atrial fibrillation and heart failure with preserved ejection fraction.

What could go wrong

This was a very small pilot study (13 participants) that was terminated early, so results are limited and may not apply to larger populations. The procedure also carries risks like bleeding, infection, or heart rhythm complications.

Conditions

The condition(s) this trial relates to.

atrial fibrillation diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.